Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00780676 · ClinicalTrials.gov registry record · Phase 2
Personalized Treatment Selection for Metastatic Breast Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
NCT00780676: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00780676 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 97 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00780676, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if researchers can use genetic tests to predict who may benefit from treatment with SprycelTM (dasatinib) or selumetinib (AZD6244).
Interventions
- DRUG Dasatinib
- DRUG AZD6244
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2009-06 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00780676
The ClinicalTrials.gov registry entry for NCT00780676 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dasatinib is the first listed.
NCT00780676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00780676 about?
NCT00780676 is a clinical study titled "Personalized Treatment Selection for Metastatic Breast Cancer". The goal of this clinical research study is to learn if researchers can use genetic tests to predict who may benefit from treatment with SprycelTM (dasatinib) or selumetinib (AZD6244).
What is the current status of trial NCT00780676?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2009-06. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00780676?
The interventions under investigation include: Dasatinib (DRUG), AZD6244 (DRUG).
Who is sponsoring clinical trial NCT00780676?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.